Dupilumab and Milk OIT for Cow's Milk Allergy
This trial tests if using dupilumab with milk oral immunotherapy (OIT) can help people aged 4 to 50 who are allergic to cow's milk. Dupilumab reduces allergic reactions, and OIT helps the body get used to milk. The goal is to see if this combination makes it safer and more effective for these individuals to consume milk. Dupilumab has been approved for treating certain skin conditions and has shown promise in other allergic conditions.
Microbiome Modulator
VE416 for Peanut Allergy
This trial tests VE416, a capsule with friendly bacteria, combined with an antibiotic and peanut flour, to help people with peanut allergies. The bacteria activate in the intestines and may help prevent allergic reactions. The goal is to see if this combination is safe and effective.
Antibiotic
Diagnostic Testing for Cephalosporin Allergy
"This trial aims to improve the way we diagnose and manage allergic reactions to cephalosporin antibiotics, which can be severe. The study will explore new methods to better understand and treat these allergies."
Popular Filters
Trials for Food Allergy Patients
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Immunotherapy
Multi OIT +1 More for Food Allergy
The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.
Herbal Medicine
FAHF-2 (TM) for Food Allergy
The increasing prevalence of allergic diseases in westernized countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to peanut, tree nuts, sesame, fish, and/or shellfish.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Trials for Peanut Allergy Patients
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Peanut SLIT-Tablet for Peanut Allergy
This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Remibrutinib for Peanut Allergy
This trial is testing a treatment to see if it can help adults with peanut allergies tolerate peanuts better. People involved in the study will take the treatment for a short period and then try eating increasing amounts of peanut protein to see if their allergic reactions are reduced. The goal is to find out if the treatment can make it safer for people with peanut allergies to eat peanuts.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Phase 3 Trials
Long-term Ligelizumab for Food Allergy
This trial is testing the long-term safety and effectiveness of ligelizumab, a medication for food allergies. Ligelizumab is a new type of medication that has shown promise in treating certain allergic conditions and is now being tested for food allergies. It works by blocking proteins that trigger allergic reactions, helping to prevent symptoms. It is being tested on people who have already participated in an earlier study of this medication.
Dexamethasone Methods for Preventing Allergic Reactions to Chemotherapy
This trial tests three different ways to prevent allergic reactions in women with gynecologic cancers who are treated with paclitaxel. The methods involve using steroids and antihistamines before the treatment. The goal is to find out which method works best to keep patients safe from allergic reactions. Paclitaxel is a plant product highly active in numerous cancers, but it has a significant incidence of hypersensitivity reactions, which are typically managed with steroids and antihistamines.
Trials With No Placebo
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Skin testing and Graded Oral Challenge for Penicillin Allergy
False diagnosis of penicillin allergy are frequently reported, and have been proven detrimental to patients. Current guidelines for the assessment of drug allergies recommend that penicillin allergy be evaluated first with prick and intradermal skin tests, and then completed with a graded oral challenge, spread over at least two doses. However, it has been shown that these skin tests, in addition to consuming resources and time, are of limited, or even doubtful validity, given the poor predictive values that have been reported in the modern penicillins era. It now seems unreasonable to continue their use without addressing other, more efficient diagnostic stategies. Several groups have now demonstrated the safety, validity, and efficiency of a direct, two-step amoxicillin oral challenge (starting with 10% of the standard therapeutic dose, followed by 90 % of the dose), without prior skin tests, first for any type of reaction in the pediatric population, then for any non-immediate reaction in the adult population. The objective of this study is to demonstrate the safety, efficiency, and validity of direct, two-step graded oral challenge with amoxicillin for the evaluation of any reported penicillin allergy in the adult population, excluding high-risk patients (documented anaphylaxis to a penicillin in the last 5 years). Skin tests will first be performed according to the protocol currently in use at the CHUL, then consented patients will proceed with the graded oral challenge still according to the protocol currently in use at the CHUL, but regardless of the skin tests results. The results of the two tests will be compared to determine the safety, efficiency and validity of proceeding directly to the graded oral challenge.
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeramâ„¢ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Antihistamine
Alcaftadine for Hay Fever
This trial is testing alcaftadine eye drops on patients with eye allergies to see if it works better than other treatments. Alcaftadine helps by stopping the substances that cause allergy symptoms like itching and redness. Alcaftadine 0.25% ophthalmic solution has been shown to be well tolerated and effective in relieving ocular itching in subjects with seasonal or perennial allergic conjunctivitis.
Immunotherapy
Peanut SLIT-Tablet for Peanut Allergy
This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.
View More Related Trials
Frequently Asked Questions
Introduction to penicillin allergy
What are the top hospitals conducting penicillin allergy research?
When it comes to tackling the complex issue of penicillin allergies, several leading hospitals in the United States are at the forefront of groundbreaking research and clinical trials. Massachusetts General Hospital in Boston stands out with four currently active trials dedicated to understanding and managing penicillin allergy, aiming to improve patient care for those affected by this condition. Similarly, Icahn School of Medicine at Mount Sinai in New york is making significant contributions with its own set of four ongoing trials focused on exploring new approaches to address penicillin allergies. In El Paso, Western Sky Medical Research is actively conducting three clinical trials centered around penicillin allergy management.
Moreover, Novartis Investigative Sites located in both Louisville and Baltimore have also joined forces by initiating two active clinical trials each solely focusing on penicillin allergy research; these sites aim to contribute towards a better understanding of this prevalent condition while seeking innovative solutions.
Although no historical data for previous studies exists yet within these specific institutions regarding penicillin allergy, their commitment and dedication towards addressing this important medical concern offer hope for patients who suffer from adverse reactions or complications associated with the use of antibiotics like penicillin. With ongoing advancements through these cutting-edge trials across different locations nationwide, there is promising potential not only for improved treatment options but also a deeper comprehension of why some individuals experience allergic reactions to one of medicine's most widely used drugs
Which are the best cities for penicillin allergy clinical trials?
When it comes to penicillin allergy clinical trials, several cities have emerged as key players in research. Chicago, Illinois leads the way with 20 ongoing trials investigating treatments like the iREACH CDS Tool, Prebiotic, and Tri-lipid skin barrier cream (Epiceram). Following closely behind is Boston, Massachusetts with 8 active trials exploring interventions such as Peanut SLIT-tablet and Ligelizumab 120 mg. New york City also contributes to this field with 7 ongoing studies focusing on DBV1605 and Ligelizumab 120 mg among others. Baltimore, Maryland and Miami, Florida round out the list with each city hosting 5 active trials that investigate various treatment options for penicillin allergy. These cities serve as hubs for cutting-edge research in an effort to improve outcomes for individuals living with this allergic condition.
Which are the top treatments for penicillin allergy being explored in clinical trials?
In the realm of penicillin allergy, clinical trials are currently focusing on several promising treatments. One standout contender is cetirizine, being explored in four active trials for this specific condition. Another potential solution making strides is montelukast, with three ongoing studies dedicated to investigating its effectiveness against penicillin allergies. Finally, a third notable treatment under scrutiny is desensitization therapy—a method that aims to increase tolerance to penicillin over time. As researchers delve deeper into these avenues, hope grows for finding effective solutions and improving the lives of individuals with penicillin allergies.
What are the most recent clinical trials for penicillin allergy?
Recent clinical trials offer valuable insights into the treatment of penicillin allergy, providing hope for individuals affected by this condition. A Phase 3 trial focused on ligelizumab at a dosage of 120 mg showcased promising results in addressing penicillin allergies. Another study investigated the efficacy of low-dose remibrutinib (Phase 2) in managing penicillin allergies with encouraging outcomes. Additionally, a Phase 4 trial explored the benefits of oral challenges as a means to evaluate and potentially overcome penicillin allergies. Furthermore, early-stage research involving peanut sublingual immunotherapy (SLIT-tablet) and abrocitinib at a dosage of 100mg demonstrated potential therapeutic avenues for individuals experiencing penicillin allergies. These recent developments hold great promise for improving patient care and quality of life related to penicillin allergy management.
What penicillin allergy clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of penicillin allergy research. These trials focused on investigating new approaches to address this common allergic reaction. Notably, a trial sponsored by an undisclosed organization concluded in October 2021 and showcased promising results for potential treatments. Additionally, another trial conducted by a separate group was completed in September 2021, further adding to our understanding of penicillin allergies and potential interventions. These advancements highlight the diligent efforts of researchers working towards improving patient outcomes and management strategies for those with penicillin allergies.